The Archive · 3 posts
Enter the next era of healthcare with Roquefort Therapeutics (ROQ)! 🧬 Innovating cancer treatments for a healthier future. Explore now! 🚀
Roquefort Therapeutics' transformative pivot: acquiring clinical-stage, brain-penetrant TACC3 inhibitor AO-252, raising £8.5m, and moving to AIM.
March 2, 2026
Showing 2 of 3 posts
Roquefort refocuses AO-252 on prostate cancer, doses first mCRPC patient, and extends its key license agreement to March 2026.
JoshuaDecember 12, 2025
Roquefort Therapeutics' reverse takeover of Coiled USA for £30m pivots to clinical-stage oncology with novel TACC3 inhibitor AO-252.
JoshuaSeptember 8, 2025